Integrated Testing Strategy

Integrated Testing Strategy


DC Role: 
Programming, developing
On going
Open to market


ITS for Skin Sensitisation

Douglas Connect acts on its vision enabling discovery and innovation through openness and integration. In this spirit, DC provides an open implementation of the integrated testing strategy (ITS) that assesses skin sensitisation potency based on the previously described approach developed at Proctor and Gamble (Jaworska et al.). The DC ITS SKINSENS implementation combines information from three validated alternative assays (DPRA, KeratinoSens and h-CLAT) with in silico predictions for bioavailability using cheminformatics tools from the community.

DC ITS SKINSENS allows scientists to evaluate the skin sensitisation hazard of their chemicals using a combination of in vitro and in silico tools. It automatically compensates for the missing experimental data by using predicted values and utilizes the expert-knowledge embedded in the skin sensitization adverse outcome pathway (AOP) as published by OECD. DC ITS SKINSENS directs consequent testing and suggest the experiments to be conducted by value of information calculations to achieve maximum information gain and reduces uncertainty in prediction. The use of Bayesian networks allows tolerating missing information and conveys the probabilistic hypothesis of skin sensitization based on accumulative evidence from data.

Why skin sensitisation?
Allergic contact dermatitis (aka., skin sensitisation) accounts for 20% of all contact dermatitis cases (“CDC - Skin Exposures and Effects - NIOSH Workplace Safety and Health Topic”; Sasseville) and hence has an estimated annual cost of $200 million (“CDC - Skin Exposures and Effects - NIOSH Workplace Safety and Health Topic”). It is also a public health problem, responsible for more than seven million outpatient visits annually. Currently, there are more than 3700 substances that are identified as contact allergens.

How does the DC ITS SKINSENS application look?
You can access the web application here. If you want to try the application on confidential molecules, please contact us for an in-house implementation. Make sure to bookmark the page!

Can I integrate the DC ITS SKINSENS into my application?
Sure! Besides the web application, we offer an API (Application Programming Interface) intended to be used as an interface by software components to communicate with each other. You read more about the API here. We are also planning for a KNIME node and a Garuda gadget for seamless integration of DC ITS SKINSENS predictions into your workflow system. Please contact us if you are interested for a free trial.


“CDC - Skin Exposures and Effects - NIOSH Workplace Safety and Health Topic.” N.p., n.d. Web. 10 Jan. 2017.
Jaworska, Joanna S. et al. “Bayesian Integrated Testing Strategy (ITS) for Skin Sensitization Potency Assessment: A Decision Support System for Quantitative Weight of Evidence and Adaptive Testing Strategy.” Archives of toxicology 89.12 (2015): 2355–2383. Print.
Sasseville, Denis. “Occupational Contact Dermatitis.” Allergy, asthma, and clinical immunology: official journal of the Canadian Society of Allergy and Clinical Immunology 4.2 (2008): 59. Print.

Latest Tweets

Edelweiss Connect (6 days ago)
Edelweiss Connect at front of the move to non-animal testing with SaferSkin™ #AnimalTesting…
Edelweiss Connect (2 weeks ago)
@UniLeiden Bob van de Water leads EU-ToxRisk. Aiming for paradigm shift in toxicological testing: reliable, animal-…
Edelweiss Connect (2 weeks ago)
#eutoxrisk Bob van de Water: "10 case studies, different partners in different disciplines, all generating data! Ed…
Edelweiss Connect (2 weeks ago)
Prof Bob van de Water, coordinator of EU-ToxRisk, largest EU programme in toxicology. 39 partner organisations acro…
Edelweiss Connect (2 weeks ago)
@UniLeiden spin-off develops 50+ cell lines “reporting” stress response signaling toxicity. Genetically-engineered…

Get in touch

  • Address: Edelweiss Connect GmbH
    Technology Park Basel
    Hochbergerstrasse 60C
    CH-4057 Basel / Basel-Stadt
  • Phone: +41 61 851 0170
  • Email: